STOCK TITAN
  1. Home
  2. News
  3. VBIV

VBI Vaccines, Inc. New - VBIV STOCK NEWS

Welcome to our dedicated page for VBI Vaccines New news (Ticker: VBIV), a resource for investors and traders seeking the latest updates and insights on VBI Vaccines New stock.

VBI Vaccines Inc. (NASDAQ: VBIV) is a leading biopharmaceutical company focused on developing next-generation vaccines to meet unmet needs in infectious diseases and immuno-oncology. Headquartered in Cambridge, MA, with research facilities in Ottawa, Canada, VBI is at the forefront of vaccine innovation with two primary platforms.

The first platform, Enveloped Virus-Like Particle (eVLP), enables the design of vaccines that closely mimic the target virus, enhancing their effectiveness. The company's lead eVLP asset is a prophylactic cytomegalovirus (CMV) vaccine, currently advancing with GMP manufacturing for formal preclinical and Phase I trials.

The second platform is a thermostable technology allowing vaccines and biologics to withstand fluctuating temperatures during storage and transport. VBI has completed proof-of-concept thermostability studies on several vaccine and biologic targets, highlighting this platform's potential to improve global vaccine distribution.

VBI's commercial product, Sci-B-Vac, is a hepatitis B (HBV) vaccine approved for adults, children, and newborns. The company's innovations are designed to address significant gaps in the vaccine market, particularly in underserved areas.

Recent achievements include the initiation of GMP manufacturing for its CMV vaccine candidate and successful proof-of-concept studies for its thermostable technology. VBI continues to be a pivotal player in the biopharmaceutical field, dedicated to advancing public health through cutting-edge vaccine solutions.

News

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

Rhea-AI Summary
VBI Vaccines expands collaboration with the Canadian government to accelerate development of its novel MLE technology platform. The partnership will direct CAD$28 million towards VBI's proprietary technology platforms, including the MLE platform, showing promising preclinical results and potential for streamlined manufacturing timelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.25%
Tags
partnership
-
News

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

Rhea-AI Summary
VBI Vaccines Inc. (VBIV) announced agreements with Brii Biosciences for up to $33 million in consideration, involving the acquisition of intellectual property, manufacturing capabilities, and exclusive licensing for immunotherapeutic candidates. The deal aims to reduce VBI's debt and enhance financial stability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.73%
Tags
none
-
News

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Rhea-AI Summary
Brii Biosciences Limited acquires all intellectual properties related to BRII-179, eliminates future milestone and royalty payments to VBI, and secures rights to VBI-1901 APAC, expanding global commercial supplies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.73%
Tags
acquisition
News

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

Rhea-AI Summary
VBI Vaccines Inc. (Nasdaq: VBIV) announced additional biomarker data from the Phase 1/2a study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients. The data showed T-cell activation capable of trafficking across the blood-brain barrier to the tumor microenvironment, with higher levels of C4G associated with longer progression-free survival. The Phase 1/2a study in recurrent GBM patients demonstrated a 44% disease control rate, with 2 partial tumor responses observed. The ongoing Phase 2b study aims to further evaluate VBI-1901's safety and efficacy in up to 60 patients with first recurrent GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.2%
Tags
clinical trial
-
News

VBI Vaccines Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
VBI Vaccines Inc. (Nasdaq: VBIV): Global net revenue for PreHevbrio, the Hepatitis B Vaccine [Recombinant], surged 52% quarter-over-quarter from Q2 to Q3 2023. The company reported continued execution across its earlier-stage pipeline, including the initiation of a Phase 2b study for VBI-1901 in recurrent glioblastoma patients, interim Phase 1 data for pan-coronavirus candidate VBI-2901, and the announcement of novel mRNA-launched eVLP platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
earnings
-
News

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

Rhea-AI Summary
VBI Vaccines Inc. has announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology. Preclinical studies have shown that the new technology generates stronger B- and T-cell signals compared to other mRNA vaccines. The technology also offers streamlined manufacturing processes and timelines. VBI's MLE technology has the potential to produce highly potent vaccines in an accelerated timeframe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.77%
Tags
none
News

VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

Rhea-AI Summary
VBI Vaccines announces positive interim data from Phase 1 clinical study of its pan-coronavirus vaccine candidate, VBI-2901. High and sustained neutralizing responses observed against COVID-19 variants and animal coronaviruses. Durability of immune responses maintained at 6 months. Safety profile consistent with VBI's eVLP platform. Funding available for next phase of clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
none
-
News

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Rhea-AI Summary
VBI Vaccines initiates Phase 2b study of cancer vaccine VBI-1901 in patients with recurrent glioblastoma (rGBM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
clinical trial
-
News

VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B

Rhea-AI Summary
BRII-179 (VBI-2601) shows positive results in Phase 2 study for hepatitis B treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
clinical trial
News

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

Rhea-AI Summary
Brii Bio announces positive results for BRII-179 in Phase 2 study for chronic hepatitis B
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
clinical trial

FAQ

What is the current stock price of VBI Vaccines New (VBIV)?

The current stock price of VBI Vaccines New (VBIV) is $0.63 as of February 7, 2025.

What is the market cap of VBI Vaccines New (VBIV)?

The market cap of VBI Vaccines New (VBIV) is approximately 1.9M.

What does VBI Vaccines Inc. focus on?

VBI Vaccines Inc. focuses on developing next-generation vaccines to address unmet needs in infectious diseases and immuno-oncology.

Where is VBI Vaccines Inc. headquartered?

VBI Vaccines Inc. is headquartered in Cambridge, MA, with research facilities in Ottawa, Canada.

What is the eVLP platform?

The eVLP platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus, enhancing their effectiveness.

What is VBI's lead eVLP asset?

VBI's lead eVLP asset is a prophylactic cytomegalovirus (CMV) vaccine currently advancing with GMP manufacturing for preclinical and Phase I trials.

What is the thermostable technology platform?

The thermostable technology platform enables the development of vaccines and biologics that can withstand fluctuating temperatures during storage and transport.

What is Sci-B-Vac?

Sci-B-Vac is a hepatitis B (HBV) vaccine developed by VBI Vaccines Inc. for adults, children, and newborns.

What are the recent achievements of VBI Vaccines Inc.?

Recent achievements include the initiation of GMP manufacturing for its CMV vaccine candidate and successful proof-of-concept studies for its thermostable technology.

What markets does VBI aim to serve?

VBI aims to serve large underserved markets, addressing significant gaps in the vaccine market, particularly in infectious diseases and immuno-oncology.

How does VBI's thermostable technology benefit global vaccine distribution?

VBI's thermostable technology benefits global vaccine distribution by enabling vaccines to withstand fluctuating temperatures during storage and transport, improving their accessibility in diverse regions.

What stage is VBI's CMV vaccine candidate currently in?

VBI's CMV vaccine candidate is currently in the GMP manufacturing stage, advancing towards formal preclinical and Phase I trials.
Stock VBIV logo
VBI Vaccines, Inc. New

Nasdaq:VBIV

VBIV Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

VBIV Stock Data

1.87M
28.68M
6.77%
13.04%
0.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE